Compare ACRS & CNNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ACRS | CNNE |
|---|---|---|
| Founded | 2012 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Restaurants |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 608.9M | 609.0M |
| IPO Year | 2015 | 2017 |
| Metric | ACRS | CNNE |
|---|---|---|
| Price | $5.71 | $14.41 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 4 |
| Target Price | $10.20 | ★ $20.25 |
| AVG Volume (30 Days) | ★ 2.0M | 447.0K |
| Earning Date | 05-07-2026 | 05-11-2026 |
| Dividend Yield | N/A | ★ 4.47% |
| EPS Growth | ★ 69.01 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $1,683,000.00 | ★ $499,700,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.24 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 3.37 |
| 52 Week Low | $1.46 | $10.46 |
| 52 Week High | $5.76 | $21.96 |
| Indicator | ACRS | CNNE |
|---|---|---|
| Relative Strength Index (RSI) | 71.95 | 53.69 |
| Support Level | $4.13 | $13.83 |
| Resistance Level | N/A | $15.03 |
| Average True Range (ATR) | 0.31 | 0.46 |
| MACD | 0.08 | 0.00 |
| Stochastic Oscillator | 92.26 | 71.75 |
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing novel drug candidates for immuno-inflammatory diseases using its proprietary KINect drug discovery platform. The company's pipeline consists of the following key product candidates: Bosakitug (ATI-045), an investigational, novel, humanized anti-TSLP monoclonal antibody being developed for patients with severe asthma, COPD, and chronic rhinosinusitis with nasal polyps; ATI-2138, being developed for the potential treatment of T cell-mediated autoimmune diseases; and ATI-052 and ATI-9494. Additionally, it has an investigational product candidate, Lepzacitinib (ATI-1777), which is being focused upon as a potential treatment for atopic dermatitis and potentially other dermatologic conditions.
Cannae Holdings Inc is an investment holding company that acquires and actively manages equity interests in operating businesses across various industries. The Company focuses on long-term ownership and seeks to create value by supporting the growth and operations of its portfolio companies through management expertise and strategic oversight. The Company operates through four reportable segments: Restaurant Group, which includes the operations of O'Charleys and 99 Restaurants; Alight, which represents its ownership interest in a technology-enabled human capital and employee benefits solutions provider; Black Knight Football Club (BKFC), which holds interests in professional football clubs; and JANA, which represents its investment in an investment management firm.